|Articles|October 19, 2016

Transplant May Still Benefit CML Patients Experiencing TKI Resistance

When CML patients develop resistance or intolerance to these drugs, transplant may be the only option.

The need for allogeneic stem cell transplant in chronic myeloid leukemia (CML) patients has decreased due to tyrosine kinase inhibitor (TKI) use. But when CML patients develop resistance or intolerance to these drugs, transplant may be the only option.

This study was recently published in the journal Clinical Lymphoma, Myeloma & Leukemia and presented (abstract CML-193) at the Society of Hematologic Oncology meeting, held September 7-11, 2016, in Houston.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Transplant May Still Benefit CML Patients Experiencing TKI Resistance

Newsletter

Related Content

Anti-CD7 Fratricide-resistant Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Myeloid Leukemia

BET Inhibition Blunts Antibody Production and Macrophage-mediated Fibrosis to Restore Lung Function in Murine cGVHD

Managing Bispecific Logistics: Remote Monitoring and CRS Mitigation Strategies

Introducing The Bispecifics Network: Importance of Education and Multi-D Care

Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease

Latest CME

Proactive Adverse Event Management for HER2+ BTC Treatments

Arizona Clinical Oncology Society

Missouri Oncology Society

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

19th Annual New York GU Cancers Congress®

Go to PER in Chicago

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breaking Down the Rationale for Targeting TROP2 in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Optimizing Treatment for Biliary Tract Cancers

Cross-Disease Integration of Immunotherapy Innovations

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Radioligand Therapy 101: The Science Behind the Strategy

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on CancerNetwork

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer

FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

Exercise Regimen Improved Outcomes Post Surgical Treatment in Breast Cancer

139 Real-World Biomarker Testing in HR+/HER2- Metastatic Breast Cancer